Protara Therapeutics, Inc. (TARA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
345 Park Avenue South
New York City, NY 10010
United States of America (the)
Phone
646 844 0337
Website
Sector
Healthcare
Industry
Biotechnology
Employees
28
First IPO Date
October 22, 2014
| Name | Title | Pay | Year Born |
| Jesse Shefferman | Co-founder, Chief Executive Officer, President & Director | 1.08M | 1972 |
| Patrick Fabbio | Chief Financial Officer | 782,409 | 1968 |
| Jacqueline Zummo | Co-Founder, Chief R&D Officer | 789,445 | 1981 |
| Leonardo Viana Nicacio | Chief Medical Officer | 872,337 | 1978 |
| Mary J. Grendell | General Counsel & Corporate Secretary | 0 | N/A |
| Carla Beckham | Lead Medical Director, Head of Clinical Development of TARA-002 in NMIBC & Board-Certified Urologist | 0 | N/A |
| Neal D. Shore | Medical Director of START Carolinas/ Carolina Urologic Research Center | 0 | N/A |
| Justine O'Malley | Senior Vice President of Investor Relations & Corporate Affairs | 0 | N/A |
| Shane Williams | Chief People Officer | 0 | N/A |
| Hannah Fry | Vice President, Principal Accounting Officer & Controller | 0 | 1991 |
| William Conkling | Chief Commercial Officer | 0 | 1972 |
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.